Group items tagged

The National Institute on Aging is seeking applications to develop systems biology approaches to understand the basic biology underpinning neurodegeneration which might ultimately contribute to Alzheimer's disease or related dementias, using non-mammalian laboratory animal models. It is expected that research carried under the auspices of this FOA will lead to discovery of new mechanisms that provoke neurodegeneration and to new molecular pathways that might be involved in causing, amplifying or protecting against neurodegeneration. Applications should propose to use established non-mammalian laboratory animals which have a history of contributions to our understanding of neurobiology or aging biology.  

This funding opportunity invites applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias (as single drugs or as drug combinations) with proof-of-concept efficacy studies in cell-based models, animal models and/or humans. 

This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimer's disease. 

This NIA Research Career Enhancement Award (K18) program invites applications from qualified researchers to acquire training and career development experiences that close expertise gaps in data science and in drug discovery. The goal of the program is to allow Alzheimer's Disease (AD) researchers to expand their expertise to become more effective in leading cross-disciplinary, translational, team-science projects in AD or AD-related dementias (ADRD). This award will also allow data scientists to redirect their expertise toward the study of AD and ADRD.

The ADDF-Harrington Scholar Program is a collaboration between the Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. The goal of developing new therapies will be achieved by providing award recipients with both research funding and committed project support by a team of pharmaceutical industry experts. Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, or slow Alzheimer's disease, other dementias, and cognitive aging.

This FY 2014 grant announcement focuses on national programs strategically targeted to address community and law enforcement needs. Specifically, this grant announcement focuses on developing community partnerships to assist law enforcement in locating and working with missing persons with Alzheimer's disease and related dementias. This initiative is funded under the Missing Alzheimer's Disease Patient Assistance Program.

This FOA invites applications for a Demography and Economics of Aging and AD/ADRD Coordinating Center (CC) whose purpose is to act as a hub, serving the needs of both traditional Centers on the Demography and Economics of Aging (D&E Centers) and Centers on the Demography and Economics of Alzheimer's Disease and Alzheimer's Related Dementias (D&E Centers on AD/ADRD), as well as the needs of NIA program staff. The goals of the overall D&E Center program are to seed new lines of research in a) the demography and economics of aging and b) demography, economics and health services research relevant to AD/ADRD, and to grow the number of researchers engaged in these fields through a variety of research and infrastructure activities that are built around specific research themes. The purpose of the CC is to work collaboratively with all participating Center sites to: maintain an active multi-center website; disseminate Center research advances, activities and resources to the research community, policymakers and other relevant stakeholders; maintain a centralized database to track and synthesize progress and outcomes of Center and CC activities for the purpose of annual reporting to individual Centers and to NIA Program Staff, and for future program evaluation by NIA; arrange an annual in-person meeting; foster communication and collaborative activities within and across both D&E Center programs and with other NIA research Centers; serve as the point-of-contact for the overall D&E Centers program by NIA staff, other NIA Centers and the broader scientific community.      

This FOA invites Research and Development Center (P30) grant applications in the areas of demography and economics of aging, including relevant interdisciplinary areas rooted in population-based social science research. Areas of focus that are especially encouraged are: a) socioeconomic status (SES) disparities at older ages, including geographic disparities; b) the reasons for poor U.S. performance in health and mortality in international comparisons; c) trends and dynamics in old-age disability; d) cohort trends in obesity and its sequelae; e) family demography including the demography of care and caregiving for chronic disease, disability and Alzheimer's Disease and Alzheimer's-Related Dementias (AD/ADRD); and f) long-term supports and services for the disabled elderly population. Applications that wish to focus exclusively on AD/ADRD should submit to RFA-AG-20-002. Center grant applications must include two mandatory Cores and may choose among three optional Cores. Centers are required to work collaboratively with the Coordinating Center to be funded via RFA-AG-20-003.  

The purpose of this FOA is to solicit applications for the AD/ADRD Health Care Systems Research Collaboratory ("Collaboratory", henceforth) to improve care for persons with dementia (PWD) and their caregivers through health systems. Health and long-term systems for this FOA are defined broadly and include organizations providing care across settings to include primary and specialty outpatient care, acute inpatient care, skilled nursing and other rehabilitation facilities, residential long-term care, and home and community-based services. Organizations may be traditional health care systems (e.g., health maintenance organizations, or HMOs), health insurance companies, managed care plans, home health care providers, memory clinics, nursing homes, assisted living facilities, outpatient clinics, federally-designated health centers, hospitals, and other providers of acute and long-term care.

The National Institute on Aging (NIA) solicits research projects that would advance our understanding of how protein homeostasis (proteostasis) in peripheral tissues affects brain aging, leading to the development of Alzheimers Disease (AD). Much research on AD has focused on the accumulation of aberrant protein aggregates in the brain, and in particular amyloid and Tau. Formation of aggregates due to mutations encoded in the APP gene or due to hyperphosphorylation, respectively, have been linked to familial AD. The etiology of the more common, sporadic form of AD, is less certain, although aging is considered a major risk for development of the disease. It is known that proteostasis is less efficiently maintained in all tissues with aging, and this may indicate a link between proteostasis in the periphery and the appearance of aging-related diseases and conditions, including the decline in cognitive function, as well as dementia and AD. Therefore, testing for a role of aging-related loss of peripheral proteostasis in the development of AD is the focus of this FOA.

Chronic Brain Injury is accepting seed grant proposals from cross-college teams of faculty studying topics related to traumatic brain injury, concussion and dementia, including Alzheimer's disease. Five awards of $25,000 are available, and all Ohio State faculty are eligible.

This RFA invites applications for planning awards to develop and finalize protocols for well-powered cognitive training intervention trials to remediate or prevent age-related cognitive decline as well as possibly prevent or delay the onset of mild cognitive impairment and dementia. Planning activities may include the collection of pilot data and the refinement of cognitive training protocols consistent with Stage I of the NIH Stage Model. Trial designs must justify the means used to assess cognition and to explore the underlying mechanisms of change. Such methods as structural and functional neuroimaging with biomarkers justified by an underlying model of change, CSF fluids, and blood biomarkers are appropriate candidate tools.

The Administration on Aging will hold a competition for a new cooperative agreement to continue operation of a national information and counseling service for persons with Alzheimer’s disease, their family members and caregivers (National Alzheimer’s Call Center). The National Call Center will be available to people in 56 states and territories, 24 hours a day, 7 days a week, 365 days a year to provide expert advice, care consultation, information and referrals at the national and local levels, regarding Alzheimer’s disease and related dementias (ADRD).

This FOA invites existing Alzheimer's Disease Patient Registry cooperative agreements that are described in Part 2, Section I to submit revision and or renewal applications. The Alzheimer's Disease (AD) Patient Registry is a population-based longitudinal cohort study of AD and dementia that is linked to an HMO-medical record system or a similar record system. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application.

This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and Alzheimer's disease-related dementias (AD/ADRD).

In addition to providing respite care and enjoyable group activities that build on the strengths and abilities of participants, the programs offer family caregivers access to services such as counseling, support groups, information and referral, training, and education. With a nationwide network of programs providing regular respite services, the program demonstrates that a cost-effective social model of adult day services can successfully address the special needs of Alzheimer's families. To that end, grants of up to $15,000 will be awarded to up to fifteen Group Respite and Early Memory Loss programs to develop a new dementia-specific social model program. Grant funds may not be used to support or expand the hours, days, or service capacity of existing social, health, or medical model programs or to serve mixed populations. Applications must be received no later than June 27.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and ADRD.

Clinical trials for Alzheimer's disease and related dementias have been hindered, in part, by the limited number of biomarkers available to (1) accurately diagnose these diseases, (2) enrich and stratify patient cohorts, (3) demonstrate target engagement for novel therapeutics, and (4) reliably monitor disease progression and response to treatment. While currently available biomarkers have helped to accelerate clinical trials, most are either expensive, invasive, or both, and provide information on a small number of disease targets. Thus, additional biomarkers are needed to provide a more complete picture of the disease.

This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The goal is three-fold: to advance understanding of